Theory Paper IIIDrNB Cardiology – Theory Notes

ADVANCES IN MANAGEMENT OF CTEPH

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IINTRODUCTION AND DIAGNOSTIC ADVANCES

  • Definition: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a progressive Group 4 Pulmonary Hypertension characterized by organized fibrotic thromboemboli in the pulmonary arteries and a secondary microvascular arteriopathy.
  • Hemodynamic Criteria: Mean pulmonary artery pressure (mPAP) greater than 20 mmHg, pulmonary arterial wedge pressure (PAWP) 15 mmHg or less, and pulmonary vascular resistance (PVR) greater than 2 Wood Units after 3 or more months of effective anticoagulation.
  • Imaging Advances: While planar V/Q scan remains the Class I screening tool, Dual-Energy CT (DECT) and 3D V/Q SPECT have emerged as advanced modalities to map the pulmonary tree and assess segmental operability without invasive angiography.

IISURGICAL ADVANCES: REFINING THE GOLD STANDARD

  • Surgical Technique: Pulmonary Endarterectomy (PEA) performed under Deep Hypothermic Circulatory Arrest (DHCA) enables surgeons to dissect the fibrotic intimal layer down to the sub-segmental level, expanding the boundaries of operability.
  • Clinical Evidence: Data from the International CTEPH Registry show that in high-volume expert centers, operative mortality has fallen to less than 5 percent, with sustained reductions in PVR.
  • Guideline Recommendation: Class I, LOE B for all patients with anatomically accessible (operable) CTEPH.

IIIINTERVENTIONAL ADVANCES: THE CATH-LAB REVOLUTION

  • Balloon Pulmonary Angioplasty (BPA): Uses coronary or peripheral balloons to crack and dilate organized fibrotic webs in distal, surgically inaccessible branches over 4 to 6 staged sessions.
  • The Landmark Evidence (RACE Trial): Compared BPA versus Riociguat in inoperable CTEPH and demonstrated that BPA provides superior hemodynamic improvements (reduction in PVR) compared to medical therapy, though it carries a higher upfront risk of Reperfusion Pulmonary Edema (RPE).
  • Guideline Recommendation: Class I, LOE B for technically inoperable CTEPH or persistent/recurrent PH after PEA.

IVPHARMACOLOGICAL ADVANCES: TARGETING THE MICROVASCULATURE

ASoluble Guanylate Cyclase (sGC) Stimulators

  • Mechanism (Riociguat): Directly sensitizes sGC to endogenous nitric oxide and stimulates the receptor independently of NO, causing pulmonary vasodilation.
  • Landmark Trials (CHEST-1 and CHEST-2): Demonstrated significant improvements in 6-minute walk distance (6MWD) and PVR.
  • Guideline Recommendation: Class I, LOE B as the approved drug for inoperable CTEPH or persistent/recurrent PH post-PEA.

BEndothelin Receptor Antagonists (ERAs)

  • Landmark Evidence (MERIT-1 Trial): Showed that adding Macitentan significantly improves PVR in inoperable CTEPH patients, supporting combination medical therapy.
  • Guideline Recommendation: Class IIb, LOE B for symptomatic inoperable patients.

CSubcutaneous Prostacyclins

  • Landmark Evidence (CTREPH Trial): Demonstrated the efficacy of subcutaneous Treprostinil in severe inoperable CTEPH, providing a rescue option for WHO Functional Class III/IV patients.
Modality / Agent Target Pathology Landmark Trial / Registry Guideline Status
Pulmonary Endarterectomy (PEA) Proximal / segmental fibrotic thromboemboli International CTEPH Registry Class I, LOE B for operable CTEPH
Balloon Pulmonary Angioplasty (BPA) Distal, surgically inaccessible webs RACE Trial Class I, LOE B for inoperable or persistent post-PEA PH
Riociguat (sGC Stimulator) Secondary distal microvascular arteriopathy CHEST-1 & CHEST-2 Trials Class I, LOE B for inoperable or persistent post-PEA PH
Macitentan (ERA) Microvascular remodeling MERIT-1 Trial Class IIb, LOE B in symptomatic inoperable CTEPH
Subcutaneous Treprostinil Severe microvascular disease (WHO FC III/IV) CTREPH Trial Rescue therapy in severe inoperable CTEPH

VTHE PARADIGM SHIFT AND THE INDIAN CLINICAL CONTEXT

  • The Multimodal CTEPH Heart Team (Class I, LOE C): CTEPH management has shifted from a binary operable-versus-inoperable approach to a hybrid multimodal paradigm where a single patient may undergo PEA for proximal clots, followed by BPA for residual distal webs, and lifelong Riociguat for microvascular disease.
  • Diagnostic Mimics in the Indian Context: In the Indian subcontinent, Fibrosing Mediastinitis (post-Tuberculosis) and Takayasu Arteritis frequently mimic CTEPH on imaging; detailed clinical history and DECT are essential to rule these out before attempting PEA or BPA.
  • BPA Accessibility: Because expert PEA surgical centers are concentrated in a few major metropolitan cities, BPA serves as an important frontline intervention in Tier-1 catheterization laboratories across India for patients who cannot access open-heart surgery.

Key references

  • Libby P, Bonow RO, Mann DL, Tomaselli GF, Bhatt DL, Solomon SD: Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 12th Ed., Elsevier, 2022.
  • Ghofrani HA, D’Armini AM, Grimminger F, et al. (CHEST-1 Investigators): Riociguat for the treatment of chronic thromboembolic pulmonary hypertension, New England Journal of Medicine.
  • Jaïs X, Brenot P, Bouvaist H, et al. (RACE Investigators): Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE), The Lancet Respiratory Medicine.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.